论文部分内容阅读
临床上血管扩张剂治疗对严重充血性心力衰竭病人有重要作用。充血性心力衰竭多为慢性,因而最近注目于血管扩张剂的长期疗效。许多血管扩张剂治疗心绞痛和高血压的观察提示多数目前用于治疗充血性心衰的血管扩剂,至少从理论上考虑,其长期应用降低效应。然而多数药物无长期对照研究评价其血液动力学效应降低的程度或临床的重要性。血管扩张剂作用减弱可能系几种不同的分子和神经内分泌机制。这些机制的相对重要性和复合作用对每一类型的血管扩张剂则不同。
The clinical treatment of vasodilators in patients with severe congestive heart failure has an important role. Chronic heart failure, mostly chronic, and therefore recently focused on the long-term efficacy of vasodilators. The observation that many vasodilators in the treatment of angina pectoris and hypertension suggest that most agents currently used to treat vasodilators in congestive heart failure have, at least theoretically, their long-term effect of reducing the effect. However, most drugs have no long-term controlled study to evaluate the extent or clinical significance of their hemodynamic effects. Vasodilator effects may be due to several different molecular and neuroendocrine mechanisms. The relative importance and the compounding effect of these mechanisms are different for each type of vasodilator.